Yearly STL Archives: 2010

Update on Drugs and Drug News: February 2010

Update on Imiquimod 3.75% Cream Zyclara™, Acyclovir + Hydrocortisone Cream Xerclear®/Lipsovir®, as well as drug news on Titanium dioxide (TiO2).

Drug Treatments for Skin Disease Introduced in 2009

An overview and update of skin conditions and treatments introduced in 2009 including Imiquimod Cream 3.75% Zyclara™, Telavancin Vibativ™, Photopheresis System THERAKOS™ CELLEX™, Romidepsin ISTODAX®, Levocetirizine Dihydrochloride XYZAL®, Calcitriol Ointment Vectical™, Etanercept Enbrel® and other drugs.

Pruritus: Control of Itch in Patients Undergoing Dialysis

Chronic kidney disease-associated pruritus is a significant clinical symptom affecting more than 50% of patients on hemodialysis. Treatment of Chronic kidney disease-associated pruritus should be undertaken according to individual benefit-risk ratio assessments.

Update on Drugs and Drug News: January 2010

Update on Capsaicin 8% Patch Qutenza™, Alitretinoin Capsule Toctino® as well as news about a recent study by Kenter et al.* explored the efficacy of a human papillomavirus (HPV) vaccine.

Predictive Testing of the Melanocortin 1 Receptor for Skin Cancer and Photoaging

Genetic predisposition to melanoma and nonmelanoma skin cancer extends far beyond the Fitzpatrick phenotype classification scheme. Testing aimed at improving prognostication may serve to limit the influence of certain risk factors.

Retapamulin: What is the Role of this Topical Antimicrobial in the Treatment of Bacterial Infections in Atopic Dermatitis?

In atopic dermatitis, the stratum corneum of patients appears to have alterations that predispose them to colonization and invasion by various bacteria. Retapamulin appears to be a much needed antimicrobial option for treating the atopic dermatitis population due to their common carriage of bacterial pathogens.